Ardelyx: 3 Key Takeaways for Long-Term Investors
On its third quarter of 2026 earnings call, held on Nov. 3, 2026, Ardelyx(NASDAQ:ARDX) reported total product revenue of $125.5 million. Expanding patient adoption and strategic clinical trials support the company's path toward commercial profitability in 2027. Three key takeaways from management's presentation stand out for long-term investors.
1. Phase 3 ACCEL Trial Reaches Full Enrollment Ahead of Schedule
Management completed patient enrollment early for its Phase 3 ACCEL clinical trial evaluating IBSRELA in chronic idiopathic constipation, or CIC, which is a long-term digestive condition with no known cause. Expanding into CIC offers access to a large patient population that shares symptoms with existing indications, creating a growth driver for the product line.
Our most advanced program with IBSRELA is our ACCEL Phase III clinical trial in patients with chronic idiopathic constipation or CIC. Today, we announced that we have fully enrolled the trial ahead of schedule.
-- Michael Raab, President and Chief Executive Officer
2. Field Support Expansion Targets Prior Authorization Friction
Healthcare providers face administrative friction when submitting prior authorizations, which are insurance approvals required before coverage begins. Management expanded its field reimbursement team to help medical offices navigate payer paperwork and convert prescriptions into completed fills.
In addition, we doubled our field reimbursement team to help HCPs navigate the prior authorization landscape.
-- Michael Raab, President and Chief Executive Officer
3. High Gross Margins Support Path to 2027 Profitability
Net loss narrowed to $700,000 in the third quarter while gross profit margins exceeded 95%. High gross margins combined with disciplined operating expenses, or opex, create financial leverage as revenue expands toward long-term targets.
Considering our greater than 95% gross profit margin and prudently managed opex, we anticipate our operating margin to grow as we move forward. That is the leverage of this business that I hope our shareholders appreciate.
-- Sue Hohenleitner, Chief Financial Officer
Looking Ahead
Commercial momentum continues across both commercial medicines, highlighting the strength of the business model. The company relies on gross margins above 95%, proprietary pharmacy distribution, and patent protection to support expansion. Leadership is watching gross-to-net realization, which measures revenue remaining after payer rebates.
Our focus is now to leverage that foundation and to build a pipeline to create long-term value.
-- Michael Raab, President and Chief Executive Officer
Focus remains fixed on achieving profitability in 2027 while advancing Phase 3 clinical assets.
We're a company with 2 first-in-class medicines, a solid financial foundation, a developing pipeline anchored by tenapanor and a team that has demonstrated that it can execute.
-- Michael Raab, President and Chief Executive Officer
Should you buy stock in Ardelyx right now?
Before you buy stock in Ardelyx, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Ardelyx wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflixmade this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $342,020!* Or when Nvidiamade this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,270,017!*
Now, it's worth noting Stock Advisor's total average return is 885% — a market-crushing outperformance compared to 208% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor , and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of November 4, 2026.
The Motley Fool recommends Ardelyx. The Motley Fool has a disclosure policy .
Ardelyx: 3 Key Takeaways for Long-Term Investors was originally published by The Motley Fool
